Conversion Therapy Using TACE/HAIC With Anti-Angiogenic and Immunotherapy for Initially Unresectable Hepatocellular Carcinoma Achieving Complete Response or Resectability, Followed by Surgery or Continued Systemic Treatment: A Prospective Cohort Study

NCT07206511 · clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
278
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

Shanghai Zhongshan Hospital